Octreotide-based solutions for agriculture, livestock, and athletic performance

Publication ID: 24-11857595_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Octreotide-based solutions for agriculture, livestock, and athletic performance,” Published Technical Disclosure No. 24-11857595_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857595_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,595.

Summary of the Inventive Concept

This inventive concept leverages the core technology of oral drug delivery of octreotide to create novel applications in agriculture, livestock, and athletic performance, addressing unmet needs in these fields.

Background and Problem Solved

The original patent focuses on treating diseases, particularly acromegaly, using oral drug delivery of octreotide. However, this technology has untapped potential in other industries. For instance, in agriculture, crop growth and livestock feed optimization are critical areas where octreotide can play a vital role. Similarly, in athletic performance, personalized training recommendations based on growth hormone and insulin-like growth factor-1 levels can revolutionize the industry. The new inventive concept addresses these unmet needs by applying the core technology to these novel fields.

Detailed Description of the Inventive Concept

The inventive concept encompasses a range of applications, including a system for monitoring and controlling crop growth, a method for optimizing livestock feed, a device for detecting and treating fungal infections in plants, a system for enhancing athletic performance, and a method for reducing pesticide use in agriculture. These applications utilize octreotide's ability to regulate growth hormone and insulin-like growth factor-1 levels, enabling precise control over crop growth, livestock development, and athletic performance. The new claims describe specific components and operations, such as sensors, controllers, and databases, that facilitate these novel applications.

Novelty and Inventive Step

The new claims introduce a paradigm shift by applying the core technology of oral drug delivery of octreotide to entirely new industries, demonstrating a non-obvious and innovative leap beyond the original patent's disease-treatment focus.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include using different formulations of octreotide, integrating with existing agricultural or athletic performance systems, or incorporating machine learning algorithms to optimize crop growth, livestock feed, or athletic training. Variations may also involve adapting the technology for use in other industries, such as veterinary medicine or environmental monitoring.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the agriculture, livestock, and athletic performance industries, with potential applications in crop growth optimization, livestock feed enhancement, and personalized athletic training. The market for these applications is substantial, with the global agricultural technology market projected to reach $22.5 billion by 2025 and the athletic performance market expected to reach $1.5 billion by 2027.

CPC Classifications

SectionClassGroup
A A61 A61K38/08
A A61 A61K9/0053
A A61 A61K9/4858
A A61 A61K38/31
A A61 A61P5/06

Field of Art

Pharmaceutical biotechnology, drug delivery systems, and growth hormone regulation, with expertise in oral drug formulation, endocrine system modulation, and biological performance optimization

Person of Ordinary Skill (PHOSITA) Profile

A professional with advanced degrees in pharmaceutical sciences, biotechnology, or related fields, possessing knowledge of drug delivery mechanisms, growth hormone interactions, and interdisciplinary applications of biological compounds

Obviousness Rationale

A PHOSITA would recognize that the core mechanism of octreotide's growth hormone regulation disclosed in the source patent provides a foundational technology that can be readily extended to multiple domains. The PTD's applications leverage the well-understood biological principles of growth hormone and insulin-like growth factor-1 modulation through a predictable oral delivery mechanism. The variations represent logical extensions of the original patent's core technological insights, applying known pharmacological principles to solve problems in agriculture, livestock management, and performance optimization.

Obvious Combinations & Variations

Source Patent Element
Oral administration of octreotide with specific dosage form and timing
PTD Variation
Oral administration of octreotide in agricultural and athletic performance contexts
Obviousness Reasoning
Known technique of modifying biological systems through controlled hormone delivery, with predictable results across different application domains
Source Patent Element
Monitoring IGF-1 and clinical symptoms
PTD Variation
Monitoring growth hormone levels in crops, livestock, and athletes for performance optimization
Obviousness Reasoning
Extending established diagnostic monitoring techniques to new fields using a known biological marker with predictable measurement approaches
Source Patent Element
Enterically coated capsule for drug delivery
PTD Variation
Sensor and controller systems integrating octreotide delivery with environmental monitoring
Obviousness Reasoning
Applying known pharmaceutical delivery principles to create integrated technological systems with finite, predictable design options
Source Patent Element
Treatment method involving H2-receptor antagonist and specific administration timing
PTD Variation
Adaptive systems for adjusting treatment based on biological marker measurements
Obviousness Reasoning
Utilizing known feedback control mechanisms common in pharmaceutical and biological systems to create responsive technological interventions
Source Patent Element
Octreotide dosage for treating acromegaly
PTD Variation
Octreotide applications in pest control and agricultural management
Obviousness Reasoning
Extending known biological interaction principles to create novel pest management strategies using established pharmacological compounds
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857595, a person having ordinary skill in the art would find the variations disclosed herein to be obvious extensions of the prior art, representing predictable applications of known pharmaceutical and biological principles across multiple technological domains. The disclosed methods and systems represent combinations of known elements producing expected results within the ordinary capabilities of skilled practitioners in pharmaceutical biotechnology and related fields.

Original Patent Information

Patent NumberUS 11,857,595
TitleMethod of treating diseases
Assignee(s)Amryt Endo, Inc.